Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00861705 · OUTCOME

Incidence and Severity of Post-op Complications, Namely Excessive Bleeding, Delayed Wound Healing, and Wound Dehiscence.

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery · Source last updated 2026-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants with event
Interval / dispersion
95% Confidence Interval
Time frame
at definitive surgery, up to 28 weeks

What was measured

Assessed by physician observation.

Groups in this outcome

Factor B: Bevacizumab

Factor B is the addition or not of bevacizumab: the experimental regimens included bevacizumab (Arms 2 \& 4).

Factor B: No Bevacizumab

Factor B is the addition or not of bevacizumab: the control regimens did not include bevacizumab (Arms 1 \& 3)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Factor B: Bevacizumab213
Factor B: No Bevacizumab214

Reported measurements

Excessive bleeding
Values in percentage of participants with event · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Factor B: Bevacizumab0Not reported02Not reported
Factor B: No Bevacizumab0Not reported03Not reported
Delayed healing
Values in percentage of participants with event · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Factor B: Bevacizumab1Not reported03Not reported
Factor B: No Bevacizumab0Not reported03Not reported
Wound dehiscence
Values in percentage of participants with event · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Factor B: Bevacizumab1Not reported14Not reported
Factor B: No Bevacizumab0Not reported03Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        2
        value
        0
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        3
        value
        0
    title
    Excessive bleeding
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        3
        value
        1
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        3
        value
        0
    title
    Delayed healing
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        4
        value
        1
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        3
        value
        0
    title
    Wound dehiscence
denoms
  1. counts
    1. group Id
      OG000
      value
      213
    2. group Id
      OG001
      value
      214
    units
    Participants
description
Assessed by physician observation.
dispersion Type
95% Confidence Interval
groups
  1. description
    Factor B is the addition or not of bevacizumab: the experimental regimens included bevacizumab (Arms 2 \& 4).
    id
    OG000
    title
    Factor B: Bevacizumab
  2. description
    Factor B is the addition or not of bevacizumab: the control regimens did not include bevacizumab (Arms 1 \& 3)
    id
    OG001
    title
    Factor B: No Bevacizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
at definitive surgery, up to 28 weeks
title
Incidence and Severity of Post-op Complications, Namely Excessive Bleeding, Delayed Wound Healing, and Wound Dehiscence.
type
SECONDARY
unit Of Measure
percentage of participants with event

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice